References
- Arnon SS, Schechter R, Inglesby TV et al. Botulinum toxin as a biological weapon: medical and public health management. JAMA285, 1059–1070 (2001).
- Simpson LL. Identification of the major steps in botulinum toxin action. Annu. Rev. Pharmacol. Toxicol.44, 167–193 (2004).
- Comella CL, Simpson LL, Jankovic J. Botulinum toxins. Transformation of a toxin into a treatment. In: From Neuroscience to Neurology. Waxman S (Ed.). Elsevier Academic Press, Amsterdam, The Netherlands 125–139 (2005).
- Caya JC, Agni R, Miller JE. Clostridium botulinum and the clinical laboratorian: a detailed review of botulism, including biological warfare ramifications of botulinum toxin. Arch. Pathol. Lab. Med.128, 653–662 (2004).
- Sobel J. Botulism. Clin. Infect. Dis.41(8), 1167–1173 (2005).
- Jost WH. Botulinum toxin in painful diseases. In: Pain and Headache (Volume 14). Karger, Basel, Switzerland 174 (2003).
- Felber ES. Botulinum toxin in primary care medicine. J. Am. Osteopath. Assoc.106, 609–614 (2006).
- Loder E, Biondi D. Use of botulinum toxins for chronic headaches: a focused review. Clin. J. Pain18, S169–S176 (2002).
- Maksymowych AB, Simpson LL. Binding and transcytosis of botulinum neurotoxin by polarized human colon carcinoma cells. J. Biol. Chem.273, 21950–21957 (1998).
- Ahsan CR, Hajnoczky G, Maksymowych AB, Simpson LL. Visualization of binding and transcytosis of botulinum toxin by human intestinal epithelial cells. J. Pharmacol. Exp. Ther.315, 1–8 (2005).
- Schiavo G, Matteoli M, Montecucco C. Neurotoxins affecting neuroexocytosis. Physiol. Rev.80, 717–766 (2000).
- Jankovic J, Hallett M. Therapy with Botulinum Toxin. Marcel Dekker, NY, USA 608 (1994).
- Smith LA. Development of recombinant vaccines for botulinum neurotoxin. Toxicon36, 1539–1548 (1998).
- Byrne MP, Smith LA. Development of vaccines for prevention of botulism. Biochimie82, 955–966 (2000).
- Maksymowych AB, Simpson LL. Structural features of the botulinum neurotoxin molecule that governs binding and transcytosis across polarized human intestinal epithelial cells. J. Pharmacol. Exp. Ther.310, 633–641 (2004).
- Ravichandran E, Al-Saleem FH, Ancharski DM et al. A trivalent vaccine against botulinum toxin (serotypes A,B, and E) that can be administered by the mucosal route. Infect. Immun.75, 3043–3054 (2007).
- Mahmut N, Inoue K, Fujinaga Y et al. Mucosal immunisation with Clostridium botulinum type C 16 S toxoid and its non-toxic component. J. Med. Microbiol.51, 813–820 (2002).
- Strayer MS, Maksymowych AB, Ruley KM et al. Adenovirus immunization against botulinum toxin. Neurotox. Res.9, 243–248 (2006).
- Zeng M, Xu Q, Elias MD et al. Protective immunity against botulism provided by a single dose vaccination with an adenovirus-vectored vaccine. Vaccine15(43), 7540–7548 (2007).